Regarding BBIO (NASDAQ:BBIO), we observe a call option trade with bullish sentiment. It expires in 78 day(s) on May 16, 2025. Parties traded 50 contract(s) at a $30.00 strike. The total cost ...

Feb. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today that it intends to offer, subject to market conditions and ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price target hoisted by Scotiabank from $49.00 to $52.00 in a research ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports ...

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

BridgeBio Pharma (BBIO) stock in focus as its 2024 spinout BridgeBio Oncology merges with Helix to form go public on Nasdaq ...

Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a report issued on Monday, February 24th. Leerink Partnrs analyst M.

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

NASDAQ BBIO opened at $36.85 on Friday. The firm’s fifty day moving average price is $31.90 and its 200 day moving average price is $27.98. The company has a market capitalization of $6.96 ...

In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against other best performing mid cap stocks to buy according to analysts. On February 7 ...